- Report
- April 2025
- 200 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- February 2024
- 74 Pages
Global
From €3500EUR$4,119USD£3,077GBP
Dactinomycin is a chemotherapy drug used to treat ovarian cancer. It is a type of anthracycline antibiotic, which works by interfering with the growth of cancer cells. It is usually given intravenously, and is often used in combination with other drugs. Common side effects include nausea, vomiting, hair loss, and fatigue.
Dactinomycin is a widely used drug for ovarian cancer, and is often used in combination with other drugs. It is generally well tolerated, and has been shown to be effective in treating the disease. It is also used in combination with other drugs to treat other types of cancer, such as breast cancer.
The dactinomycin market is highly competitive, with many companies offering the drug. Some of the major players in the market include Pfizer, Merck, Bristol-Myers Squibb, and AstraZeneca. Other companies include Novartis, Sanofi, and GlaxoSmithKline. Show Less Read more